[1] 孟广蕊,田勇,纪志芳. 耳穴压豆联合胺碘酮治疗阵发性心房颤动的临床观察[J]. 深圳中西医结合杂志,2022,32(7):33-35. DOI:10.16458/j.cnki.1007-0893.2022.07.010.
[2] 肖慧,卢昊阳,代曼玉,等. 基于老年持续性心房颤动患者左心房基质消融与后壁线性隔离消融策略的对比性研究[J]. 安徽医科大学学报,2022,57(11):1844-1848.DOI:10.19405/j.cnki.issn1000-1492.2022.11.029.
[3] Ha ACT, Wijeysundera HC, Qiu F, et al. Differences in healthcare use between patients with persistent and paroxysmal atrial fibrillation undergoing catheter-based atrial fibrillation ablation: a population-based cohort study from Ontario, Canada[J].J Am Heart Assoc,2021,10(1):e016071.DOI:10.1161/JAHA.120.016071.
[4] 吴治胜,史琪,武洋,等. 实时三维超声心动图评价心房颤动患者射频消融术前后左心房功能及二尖瓣构型的变化[J]. 中国医学影像学杂志,2021,29(2):142-147.DOI:10.3969/j.issn.1005-5185.2021.02.010.
[5] Nagy Z, Kis Z, Géczy T, et al. Prospective evaluation of iatrogenic atrial septal defect after cryoballoon or radiofrequency catheter ablation of atrial fibrillation-"EVITA" study[J].J Interv Card Electrophysiol,2019,56(1):19-27.DOI:10.1007/s10840-019-00598-9.
[6] 卢昊阳,赵韧,卢家忠,等.血浆大内皮素1和白细胞介素17A及左心耳体积与心房颤动经射频消融术后复发的相关性[J].中华老年心脑血管病杂志,2022,24(7):705-708.
[7] Ruan ZB, Gao RF, Wang F, et al. Circulating galectin-3 and aldosterone for predicting atrial fibrillation recurrence after radiofrequency catheter ablation[J].Cardiovasc Ther,2022,2022:6993904.DOI:10.1155/2022/6993904.
[8] 黄从新,张澍,黄德嘉,等. 心房颤动:目前的认识和治疗建议(2018)[J]. 中华心律失常学杂志,2018,22(4):279-346. DOI:10.3760/cma.j.issn.1007-6638.2018.04.002.
[9] 王建铭,黄从新. 房颤射频消融术后的早期复发与晚期复发[J]. 中国心血管病研究,2016,14(5):385-388.DOI:10.3969/j.issn.1672-5301.2016.05.001.
[10] Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association[J].Circulation,2019,139(10):e56-e528.DOI:10.1161/CIR.0000000000000659.
[11] 康哲锋,石峻,郭应强. 全胸腔镜下Box Lesion射频消融术治疗心房颤动近中期效果评估[J]. 中国胸心血管外科临床杂志,2021,28(9):1066-1071.DOI:10.7507/1007-4848. 202104044.
[12] 王鹏宇,郝应禄,李燕萍,等. 房颤围术期利伐沙班不间断与间断抗凝的有效性及安全性观察[J]. 中国医学创新,2021,18(32):139-143.DOI:10.3969/j.issn.1674-4985.2021. 32.035.
[13] Yang S, Mei B, Feng K, et al. Long-term results of surgical atrial fibrillation radiofrequency ablation: comparison of two methods[J].Heart Lung Circ,2018,27(5):621-628.DOI:10.1016/j.hlc.2017.04.016.
[14] 王喆,郭和合,刘志煜,等. 左心耳及其毗邻形态结构对心房颤动导管射频消融术后复发的预测价值[J]. 郑州大学学报(医学版),2021,56(2):216-221.DOI:10.13705/j.issn.1671- 6825.2020.06.020.
[15] 张雨,何非,盛建龙,等. CHADS2及CHA2DS2-VASC评分对心房颤动射频消融术后晚期复发的预测价值[J]. 安徽医科大学学报,2022,57(7):1138-1142.DOI:10.19405/j.cnki.issn1000-1492.2022.07.023.
[16] 李闪悦,邓通元,吴君玲. 心房颤动患者心脏射频消融术后复发的影响因素分析[J]. 实用心脑肺血管病杂志,2021,29(1):21-27.DOI:10.12114/j.issn.1008-5971.2021. 01.005.
[17] Brooks S, Metzner A, Wohlmuth P, et al. Insights into ablation of persistent atrial fibrillation: Lessons from 6-year clinical outcomes[J].J Cardiovasc Electrophysiol,2018,29(2):257-263.DOI:10.1111/jce.13401.
[18] 闫丽,邵旭华. 瓣膜置换同期改良迷宫射频消融术后患者早期房颤复发危险因素分析[J]. 当代护士(上旬刊),2022,29(3):57-60.DOI:10.19791/j.cnki.1006-6411.2022. 07.014.
[19] 李晶晶,崔英凯,李俊峡,等. CARTO系统引导下射频消融治疗老年心房颤动的术后复发相关因素分析[J]. 中国循证心血管医学杂志,2018,10(10):1182-1185.DOI:10.3969/j.issn.1674-4055.2018.10.08.
[20] Wang A, Green JB, Halperin JL, et al. Atrial fibrillation and diabetes mellitus: JACC review topic of the week[J].J Am Coll Cardiol,2019,74(8):1107-1115.DOI:10.1016/j.jacc.2019.07.020.
[21] Karam BS, Chavez-Moreno A, Koh W, et al. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes[J].Cardiovasc Diabetol,2017,16(1):120.DOI:10.1186/s12933-017-0604-9.
[22] 曹佐锋,何苗,王小萍,等. 体重指数联合炎症指标对房颤射频消融术后复发预测的研究[J]. 医学理论与实践,2022,35(17):2989-2991.DOI:10.19381/j.issn.1001-7585. 2022.17.046.
[23] Cao H, Chen X, Zhu X, et al. Predictors of failure cardioversion for recurrent atrial fibrillation following mitral valve surgery with ablation[J].Heart Surg Forum,2020,23(3):E300-E304.DOI:10.1532/hsf.2997.
[24] 王庆亚,林佳,张宇祯,等. 多指标联合评估模型对阵发性心房颤动导管射频消融术后复发的预测价值[J]. 临床心血管病杂志,2021,37(1):62-68.DOI:10.13201/j.issn.1001- 1439.2021.01.013.
[25] 陈社安,郑美芳,张漫漫,等. 单核细胞与高密度脂蛋白胆固醇比值对射频消融术后晚期心房颤动复发的预测价值[J]. 中华老年心脑血管病杂志,2020,22(7):680-683.DOI:10.3969/j.issn.1009-0126.2020.07.003.
[26] Yao Y, Yao W, Bai R, et al. Plasma homocysteine levels predict early recurrence after catheter ablation of persistent atrial fibrillation[J].Europace,2017,19(1):66-71.DOI:10.1093/europace/euw081.
[27] Njoku A, Kannabhiran M, Arora R, et al. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis[J].Europace,2018,20(1):33-42.DOI:10.1093/europace/eux013.
[28] 姚俊功,鲁敏,孙琳. 心房颤动患者射频消融术后晚期复发的危险因素研究[J]. 河南医学研究,2020,29(12):2131-2134.DOI:10.3969/j.issn.1004-437X.2020.12.006.
[29] Di C, Gao P, Wang Q, et al. Intraprocedural conversion efficacy of intravenous nifekalant administration for persistent atrial fibrillation after pulmonary vein isolation[J].Int Heart J,2020,61(6):1157-1164.DOI:10.1536/ihj.20-328.
[30] 刘金明,荣奥运,郝杰,等. 伊布利特注射液用于持续性心房颤动射频消融术患者的临床研究[J]. 中国临床药理学杂志,2022,38(7):623-626.DOI:10.13699/j.cnki.1001-6821. 2022.07.002.
[31] Goette A, Lendeckel U. Atrial cardiomyopathy: pathophysiology and clinical consequences[J].Cells,2021,10(10):2605.DOI:10.3390/cells10102605.
[32] 钟耀棠,李诗成,李忠荣,等. 房颤患者在RFCA术后应用药物维持与电复律对房颤晚期复发的影响对比[J]. 中外医学研究,2022,20(13):46-49.DOI:10.14033/j.cnki.cfmr.2022. 13.013.
|